Multiple reports describe the development of a new blood test designed to help detect pancreatic cancer traces that may remain after treatment. The test targets small amounts of “residue” cancer cells that scans can miss, with the goal of improving detection in patients who have already undergone therapy. The articles frame pancreatic cancer as a disease that is difficult to detect early and can be challenging to monitor afterward, partly because standard imaging may not identify very low levels of remaining disease. By using a blood-based approach, the test is presented as a potential additional tool for follow-up, aiming to identify possible persistence or recurrence earlier than current methods in some cases. The coverage does not provide detailed performance metrics, study size, or regulatory status in the supplied excerpts, but it indicates that researchers are working on a diagnostic or monitoring blood assay specifically intended to pick up minimal residual disease.